Xylometazoline-d4 (hydrochloride)

• UNSPSC Description:

  Xylometazoline-d4 hydrochloride is deuterated labeled Xylometazoline hydrochloride (HY-B0475). Xylometazoline hydrochloride is an α-adrenergic receptor agonist (Ki=0.05-1.7 μM). Xylometazoline hydrochloride can constrict nasal blood vessels and increase nasal airflow. Xylometazoline hydrochloride can be used in nose stuffiness and runny nose research[1][2].

• Target Antigen:

  Adrenergic Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=C(CC2=NC([2H])([2H])C([2H])([2H])N2)C(C)=CC(C(C)(C)C)=C1.Cl

• Molecular Weight:

  284.86

• References & Citations:

  [1]Ronald Eccles, et al. The nasal decongestant effect of xylometazoline in the common cold. Am J Rhinol. 2008 Sep-Oct;22(5):491-6.|[2]Britta Haenisch, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported